A study is to determine clinical outcome of non-small cell lung cancer patients harboring a 5' deletion confirmed by NGS as a ROS1/EZR fusion when treated with Crizotinib therapy
Latest Information Update: 29 Jul 2020
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 29 Jul 2020 New trial record